ABSTRACT
Daily doses of 30 mg of primaauino cause severe hemoly sis in G6PD deficient Caucasians. Effective weekly dosages of 4!> mg of priraaquine and 300 -mg of chloroquine do not cause s_i gnificant hemolysis in G6PD deficient Negroes. In order to investigate the upper limits of safety to primaquine, the effect of this standard weelcly dose on G6PD deficient Caucasians was studies. Seven sensitive Sardinians had significant hemolytic crises after a single weekly administration of the drugs. There was a drop in the hematocrit, a shortened survival of 51Cr tagged red cells, with an average destruction of 400 ml of red cells. GöPD deficient 51Cr tagged red cells belonging to some of these subjects transfused into normals, receiving the reafter weekly doses of primaquine, were rapidly destroyed, convalidatlng the sensitivity to primaquine. Three G6PD deficient^Sardinians did not show any hemolysis after Ingestion of weekly doses of primaquine. Their red cells, however, transfused into normals, who r ccived standard weekly doses of antimalarial-drugs, were also rapidly destroyed. Investiga tions should establish if environmental factors (faulty absor ption of primaouine, different metabolic breakdown of the drug) or metabolic differences in the 66PD deficient red cells are responsible for this peculiar behavior. As far as the protectLve role of SH donor drugs is concerned, preliminary clinical stu dies have failed to show any significant protective action oT these drugs.
The apnarent in vitro protective obtained by preincuba ting normal 'act red cells with cysteine or cysteamine prior tc the cxp f the cells tc NEM, c uld possibly be ascribed to chemic;.. reactions between the twe compounds.
Aims
The antimalarial action of primaquine is well-known: daily doses of 30 mg hpvo a uniaue ability in preventing and treating malaria. This therapeutic action has usually no side effects, with the exception of Negroes and Caucasians with red cell <}6PD deficiency.
• In G6PD deficient Negroes the daily administration of 50 or 15 mg of primaquine induces a seif-iiraited hnmolytic crisis (1). In G6FD deficient Caucasians the problem is somewhat different: the enzymatic defect of the red cells being tiiorc severe, the daily administration of 30 mg of primaquine induces serious hcmolytic episodes in which old and young red cells are destroyed. (2) The hemolytic ability of priraaauine on G6PD deficient Negroes has stimulated some investigntors to study if weekly dosages of the antimalarial drug could nullify its hcmolytic side effect. On-this assumption Alving and associates (3) have worked out a therapeutic scheme of weekly dosages of 45 mg of primanuine and 300 rag of chlcroouine which, while still preserving an effective antimalarial action, had little if any hemolytic effect on G6PD deficient Negroes. The absence of clinical signs of hemolysis when using the above-mentioned doses of prlmacuine and chloroquine has been confirmed by Ziai and Eowmann on Iranians. (4) Their study, however, was based essentially on the determination of the hematocrit level on a monthly basis, and on the presence or absence of evident clinical signs of hemolysis.
It was thought worthwhile, therefore, to undertake an investigation on the action of weekly dosages of primaquine and chloroquine on G6PD deficient Sardinian males who, as already stated, have an extremely severe deficiency of the red cell enzyme, and whose greater susceptibility to antimala rial drugs has already been ascertained.
In "vivo" studies on the possible protective effects of sulphydril donor drugs or EDTA on sensitive Sardinians and on G6PI) deficient red cells transfused into normal recipients who received thereafter antimalarial drugs, were also undertaken. Collateral investigations on the action of these pro tective drugs on NEM damaged normal red cells "in vitro" were performed in order to better understand, if possible, the relationship between oxidizing drugs, normal er G6PD deficient red cells, and SH donor compounds.
Methods and Materials
Laboratory studies Hem-itocrit, hemoglobin ;.nd blood group determinations were performed according to standard procedures.
Red blood cells were tagged with radioactive sodium chromate according to the technique of Mollison and Veall. (5) The radioactivity of the blood samples was measured in a well scintillation counter.
Erythrocytic G6PD v/as measured according to the method of Kornbcrg and Horecker. (6) Clinicai studies · (1) Ten Sardinian males · with G6PD deficiency of their red cells, and four Sardinian males w1 tl §ut red cells· abnol'ID5 lities volunteered for these studiea.eir red cella were · tagged with 51Cr and after -the baaeline aaaeaament of the red cell sUrvival, both normal controls and G6PD deficient SardiDiPns rec~ived one or more weekly doses of 45 me of primaquine -and '00 mg ot chloroquine. Theae . wer~ the standard doses used throughout this .study if not othe~ise ato.ted. I
• J
(2) G6PD .deficient r ed cells belonging to 9 Sardinian ·males, tagged with 51Cr, were transferred into normal subjects with compatible blood groups. The recipients received thereafter, weekly dosnges of primaquine nnd cbloroq_uirie ( 45 mg and ~ 300 mg) once the baseline survival of the transfused G6PD defi .£. Clent r(;!d cells ho.d be£n assessed. -: (3) Normal recipients, in whom 51Cr tagged, G6PD deficient red cella · had been tranatuaed, received before, during, ~d after t~c weekly a~ministration of the antimalarial drugs, 1-cysteine, cysteamine ·or EDTA.
L-cysteine was administered in daily oral doses Cysteamine was given perenterally in ·da.ily doses of ~A .~s administered intrave no~sly in daily doses of of 1 gm 600 mg.
2 gm.
ResUlts
'clinical Studies · ( l) Three·· normal S .rdiniRns, without r ed cell G6PD deficiency, r eceived 3 we e~ly dos~e s of primaQuine and chloro quinc (45 and 300 _ mg respectively). No ·hemolysis was observea. The survivAl of their 51CT 'tagged red cells was 28, 22, and 27 days ( fig. 1 ).
I
• · (2) · Seven out t en G6PD deficient Sardinian males, trea t ed with the stari~ard ' d o sage of antimalnrial drugs, had defi--nite hemolysis, which could be evaluated both by 51Cr tagged r ed cell survival and chnnge in the l evel of the hematocrit
In only one case (C. A.) the disappearf'Ce of the 51Cr tegged r ed cells from the circulation _ was not accompani ed by significant changes in the l evel of the heme.tocri t (fi g. 5). ·In ·thea s even cases the primaouine-chlo roquine prepe.r r:.t ion wus administer ed only onc e in three cnses-; twice in three oases, e nd three times in one case . · (3) In three G6PD defici-ent Sardinian mnl s r epeated weekly administrati ons of primaauine-chloroQuine (45 mg and 300 mg ) didn't produce nny r ed cell destructi on which could be evaluat ed by changes in hematocrit or 51Cr t agg d r ed cell sur vival (fi~. 9-10-11).
· . C4J In ~he eeven . Sard~!l:ian males who developed hemolysis, the mean . survival of the 51Cr tagged red cells before the administrati on of the an~ime.larial drugs, wa.s···21.8 days (table 1) . Is . only one case the 51Cr T/2 was 12 days although the hematocrit level was norBal• After the administration of the primaquine-chloroquine preparation (45 mg · and~OO mg), the mean 51Cr T/2 of all seven cases was-e.-7 days; · .. The mean percentage of all red cellahemolyzed was 19 perce~t i~ calculated on the hematocr~ t . levels, and 24 percent if c' alc· ulated: on 51Cr survival datar.-Tbe amount of red cells destroyed in the hemolytic crisis in th~ee cases in which the red cell mass could be calculated was 450' ml (S.A.), 390 ml·(F.U . • ), and 350 ml (M.P.). One G6PD jeficient Sardinian male (F.U.) received twice a single weekly dose of pri~aquine-chloroquine (45 mg and 300 mg) ( fig. 7} , the first dose being administered together with EDTA intravenously, the :second one with 1-cysteine orally. Each time the antimalarial .drugs have caused ·hemoly-sis with a 51Cr half life, comp~red · to that of the other susceptible cases recei. ving the . same dosages of antimalarial drugs.
. · · (5) , G6PD ' deficient red cells to be transfused into nor mal recipients who received ·. pr~maauine, were drawn from sensitive Sardinian males b~l onging to the following groupe: -a) .G6PD .deficient Sardinian males who were susceptible to the drug (point 2); b) G6PD defic~ent subjects who did not show any hemolysis after receiving the weekly dosage of primaquine (point 3}; c) G6PD deficient subjects who were not treated with primaquine • · . In all normal recipients (table 2, fig. 12 ) the administrati on of the primaquine chloroquine preparation caused a clear-cut shortening of the survival of the transfused, . sensi tive red cells. ~e an red cell survival during the baselineperiod was 21.2 days; after administration it decreqsed to a mean value of 7.1 days. Aft er a mean period of hemolysis of 4 days, the survival of the rema1ning tagged sensitive cells was normal or even longer 'than normal, probably owing to the destruction of the older cells. The mean percentage of the r ed cells hem lyzed was 31 percent. (6) . G6PD ' deficient red cells were transfused · into normal r ecipients who r eceived EDTA, .cysteine or cysteamine, before ?nd during the ad~inistrati o n of the standard dose of nntimn.larial drugs. No clear-cut modification of ·the hemolytic acti on of primaauine could be observe d i n th' ese cases . (fig. s·   end 12 ).
(7.) Normal red cells were dP.maged with BMHP-Hgl97 (which inhibits the GSH groupe of the red cell surface) and transfus ed int o the normal donors, s ome of whom·received intra venous infusi ons oftwo grams of · V1t. C. The infusions wereb~gun twenty minutes before the injection of the damaged cells, ~~d l ast ed f or a t least an hour~· No difference in the half lif . of th e damaged cells, with or without the administration c f Vit. C. cculd be observed. 
Discussion
These studies suggest that in the greater pA.rt of G6PD deficient Caucasians, the administration of single weekly dos! ges of 45 mg of prim~ouine and 300 mg of chloroQuine induces destruction of r ed cells, with changes in the hematocrit l evel, bilirubinemic , (md r eticulocyte number.
The s everity of the hemo lytic crisis differs among the aensi ti ve sub;i eta: oome of 1tlem shnwed a malttecl h emolysis with a SE!! sible drop in the hemat ocrit l evels. In three cases the amount of the r 0d cell mass destr yed hne been calculAt ed t o be Rbout ~JO ml.
Transfus i ons of G6FD defici ent r~d cells, bel onging t o this group of subj ects or t o other s ensitive Caucneiane, into normal r ecipients r eceiving th r eafter one or ~or singl e weekly dos t= s of priiDAouine , h. ve b en perfon:ted. The suscepti bili ty t o heme. lysis of C!l.ucaAians t o standard weekly dos es ofantimal arial drugs w~e f ully convalidatcd also from a quantita tive point of vi ew. In s ome r cipients repeat ed administra--ti ona of weekly dos es of 45 mg of primnquine caus ed r ed cell destruction at each ingesti on.
'
Wc-ckly doses of primaquint didn't cause any change in survival of 51Cr tagged red cells or in hematocrit levels in three aot of ten GöFD deficient Caucasian males. The peculiar behavior of these three subjects may be pessibly related to: a) faulty absorption of the single dose of priraaquinc; b) dif ferent metabolic breakdown of the drug; c) a different motabc lie pattern of the GGPD deficient rod cells of these subjects. The red cells of two of these same subjects, when transfused into normal recipients whe received 45 or 60 mg of primaquine per week, underwent a significant dtstruction. This fact would suggest the possible existence of environmental factors rather than metabolic differences' of the red cells.
Investigations are in progress in order to possibly elucidate this problem.
The results here reported are similar to those described by George and ass. (9) These authors have described hemc lytic crises following the Ingestion of a single 45 mg tablet of primaciuine in two G6PD deficient Caucasians. Two other Caucasians had ingested primaquine in weekly dosages for some months without developing hemolytic crises. These two latter cases seemed to behave like-our G6PD deficient Sardinians who received several doses of primaquine without developing hemolysis.
Äs i f-r ;?s the possible protective role of'SH donor drugs is concerned, preliminary clinical studies have failed to show any significant protective action of these drugs.
The apparent "in vitro" protective effect obtained byincubating normal intact red cells with cysteine or cysteaminc prior to the exposure of the cells to NEM, could be ascribed to chemical reactions between the two compounds. (10) ^^i Lab. Clin. Med. 61, 882, 1963 
